% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • clairient1 clairient1 Jul 13, 2005 6:50 PM Flag


    What a pile of poo. Why dont they make some products that actually help people.
    Still time to sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • How many more people will be allowed to die as they have recall after recall? I used to be a shareholder until I realized they are killing thousands of innocent people. The FDA really needs to take action before the class action lawsuits, and I will be joining the lawsuits to try to get some of my money back, but the deaths are amazing that they keep going on. And now theres another recall.
      Boston Scientific Recalls Medical Devices
      Friday December 2, 8:21 pm ET
      Boston Scientific Recalls 18,000 Vena Cava Filters on Reports of Malfunction

      NATICK, Mass. -- Boston Scientific Corp. said it is = recalling another 18,000 Vena Cava Filters after receiving reports of detachment of part of the device during the implant procedure.
      In a press release Friday, the medical device maker said if the filter's carrier capsule should detach during an implantation procedure, there is a risk of cardiac and pulmonary embolization, with potential adverse events including serious patient injury or death.

      A vena cava filter is a small cone-shaped device that is implanted in the inferior vena cava, the large vein that carries blood from the lower part of the body to the heart. The filter prevents pulmonary embolism by capturing blood clots before they can be carried to the lungs.

      The company received many complaints, several of which were reported as involving serious patient injury requiring intervention and at least one was reported as a death.

      Boston Scientific's recall involves Stainless Steel Greenfield Vena Cava Filters with 12Fr Femoral Introducer Systems manufactured before March 10, 2004. All unused devices with a "use before date" prior to March 2007 should be returned to the company.

      Specifically, Boston Scientific received reports of detachment at the bond between the carrier capsule and the outer sheath of the filter's delivery system during the implant procedure.

      The company said that an analysis of returned devices revealed the potential problem.

    • Of course the negative data on late restinosis will have a negative effect on the 6 class action lawsuits. The fact that BSX has the worst product isn't the problem, its the fact that they seem to release defective products possibly because of willful negligence.

      Studies Give Edge To J&J Stent
      Matthew Herper
      NEW YORK - Johnson & Johnson has a better product than its rival, Boston Scientific, for holding open clogged arteries.

      New data published in the two leading medical journals indicates that patients who receive Cypher, a drug-coated stent made by Johnson & Johnson (nyse: JNJ - news - people ), are far less likely to need a repeat surgery than those who get Taxus, a rivalstent from Boston Scientific (nyse: BSX - news - people ).

      That's more bad news for Boston Scientific, which has seen shares drop 30% since September 2004 amid concerns over its over-reliance on drug-coated stents.

      "There is a difference," says David J. Moliterno, a cardiologist at the University of Kentucky who wrote an editorial on the studies in The New England Journal of Medicine.
      For all patients taken as a group, Moliterno says, those who receive Taxus are much more likely to need their procedure redone than those who receive Cypher.

      High-risk patients, such as those with diabetes, also fare better with the Cypher stent, he says.

      Samin Sharma, a cardiologist at the Mount Sinai School of Medicine, say she thinks most doctors would opt to use Cypher if it weren't for persistent manufacturing problems that can make the device harder for doctors to get. He notes that the evidence is consistent that Cypher is better at preventing arteries from reclogging.

      The researchers found that patients receiving Cypher were at much lower risk of having their arteries reclose than those who received Taxus. The results are published in the current issue of The Journal of the American Medical Association. Says Firth, "I think the value of this product from a health economics standpoint is very clearly demonstrated."

    • You ask 'Does anyone know if the negative data on late restinosis could have an impact on the 6 class action lawsuits?" You must have missed the last results from the largest multicentered study ever conducted. It showed that Taxus was better than Cypher. So the answer to your question is that the latest studies will hurt the class action suits as will the rising share price of BSX as all stocks cycle, nothing goes straight up forever.

      Buy low, sell high. No suing when you're stupid.

    • Does anyone know if the negative data on late restinosis could have an impact on the 6 class action lawsuits?
      BSX no longer sells the Glidewire,glidecath or
      pinnacle sheaths? I know it is not as glamorous as
      Coronary stents but how will this affect the bottom line?

    • CONR has a better mousetrap. BSX obsolete.
      Conor Medsystems is set to take on Boston Scientific
      Medsystems Inc. (CONR ) has developed a new better breed of stent that have the power to swipe large swaths of business from rivals such as Johnson & Johnson (JNJ ) and Boston Scientific Corp. (BSX )
      J&J and Boston Scientific are the two gladiators in this field, but many physicians are keeping a close eye on Conor's product as well. Although the stent's rate of restenosis, or recurrence of arterial blockages, has been much better than Boston Scientifics, doctors say Conor's is also easier to implant is also safer and more effective.

      The Menlo Park (Calif.) company will release new data from clinical trials at a top cardiovascular meeting in Washington. "If it came out in the U.S. right now, the market would swing," says Dr. Dean Kereiakes, a professor of clinical medicine at Ohio State University who is serving as a co-principal investigator for Conor's U.S. clinical trial.

      Conor has had some success but CIBC analyst John P. Calcagnini, who has a $26 price target on the stock, believes Conor can take 11% of the market by 2006.

      Angiotech licenses a drug called paclitaxel to Boston Scientific that inhibits the growth of scar tissue. Conor uses the same drug in its clinical trials, but the way it incorporates and releases the drug is novel and doesn't infringe on its rivals' patents.

      Litvack has helped run three companies, one of which was Advanced Interventional Systems Inc. The company developed laser technology to clear up artery blockages, In 1994 it was acquired by its chief rival, Spectranetics Corp. (SPNC ), for just $12 million -- a thin sliver of the $150 million market cap it reached after going public in 1991.

      At least two physicians with no financial ties to Conor give its device high marks. Some cardiologists say Conor may succeed because its stent, which is thinner and less sticky than existing drug-coated stents, is more easily maneuvered through a clogged artery. "If everything else was me-too, just that one feature would take the whole market," says Dr. Mitchell Krucoff, a professor of medicine and cardiology at Duke University Medical Center If current clinical trials go well, Conor must battle Boston Scientific, J&J, and others. Boston Scientific is spending more than $200 million a year on interest and debt. For Litvack, the key to beating the competition is more innovation, both in devices and drugs. Conor is now developing a stent that uses anti-clotting compounds acquired from Novartis. "We believe the job of a good medical company is to make your products obsolete," he says.

    • ok i give up im selling. Stopped out
      I put in a mental stop and I was giving it a chance but this poor thing is done. Stick a fork in her shes done. Probably will go into the teens. Best of luck all.

    • Well I do think the high rate of turnover is a problem for BSX, not being able to keep key employees could lead to problems, but there appears to be a stent surplus, this glut of unused supply buildup of excess inventory could be the reason they don't need as many people since the companies sales are slowing and there is no growth. But there seems to be some real problems. Chart looks like its breaking down maybe this stock would be a good buy at $9?

    • Wow. A new lying POS appears. Who are you really? One of those who have "sold all my shares" a dozen times?

    • I just took advantage of all the hyping to sell my shares. Had to take a small loss but it was well worth it to get out of this pos. Its unbelievable that one company can screw up that much. They have earned theirselves a reputation as a joke in the industry. I think they will pull a K-mart on bagholders and once the merger is complete file chapter 11 Bankruptcy to resolve the insane debt and leave investors with nothing.

    • shirlylong42 wrote: "You know as well as I do something has to be done about all the deaths, there are thousands and thousands, that we know about."

      The FDA and companies look at complaint and death rate numbers and rates of changes of each. Alert and action rates are set at numbers less than 1%. Your claim of thousands and thousands of deaths earns you the "Ignore this user" button. Your hand in your pocket does not allow you to say "we" as in plural of I only "weee" as in you are having a good time by yourself.

      Suggest that others try the ignore button for individuals that spread garbage otherwise this site will stay a wasteland of dribble.

    • View More Messages
16.94+0.06(+0.36%)Oct 12 4:00 PMEDT